Clinical TrialsSearch results
Number of results: 69661
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- Phase II study of Rituximab in Patients with Systemic Lupus Erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-07-05
Other
- Phase II study of rituximab in patients with severe systemic lupus erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-07-05
Other
- Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.
- CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.
- ZENYAKU KOGYO CO., LTD.
- 2017-08-01
Other
- Clinical study of Rituximab for inhibition of antibody mediated rejection in ABO-incompatible kidney transplantation
- Chronic kidney disease patient to whom ABO incompatibility kidney transplantation is planned.
- Zenyaku Kogyo Co., Ltd.
- 2011-11-01
Other
- A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus
- Systemic lupus erythematosus
- Zenyaku Kogyo Co., Ltd.
- 2007-03-16
Other
- A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients with Advanced Solid Malignancies
- Advanced Solid Malignancies
- Zenyaku Kogyo Co., Ltd.
- 2012-08-31
Other
- A pharmacokinetics study of the major ingredient and its metabolites after single ingestion of test food
- Not applicable
- Zenyaku Kogyo Co., Ltd.
- 2018-02-26
Other
- A pharmacokinetics study of the major ingredient and its metabolites after multiple ingestions of test food
- Not applicable
- Zenyaku Kogyo Co., Ltd.
- 2018-10-26
Other
- A multicenter phase II open-label study in untreated patients with CD20 positive indolent B-cell non-Hodgkin's lymphoma evaluating efficacy and safety of maintenance therapy with IDEC-C2B8.
- Untreated patients with CD20 positive indolent B-cell non-Hodgkin's lymphoma.
- Zenyaku Kogyo Co., Ltd.
- 2008-12-26